newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

- AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on